NeuroPace (NPCE) Stock Fair Value Falls After Analysts Cut Targets On Q3 Miss
HC Wainwright & Co. Maintains Buy on NeuroPace, Lowers Price Target to $12
NeuroPace, Inc. Q3 2026 Earnings Call Summary
Keybanc Maintains Overweight on NeuroPace, Lowers Price Target to $14
Leerink Partners Downgrades NeuroPace to Market Perform, Announces $7 Price Target
NeuroPace (NPCE) Q3 2026 Earnings Call Transcript
What NeuroPace (NPCE) Said on Its Q3 Earnings Call
NeuroPace Shares Plunge 33.61% After-Hours: Here's What Investors Should Know
NeuroPace, Inc. (NPCE) Q3 2026 Earnings Call Transcript
NeuroPace Inc.: Q3 Earnings Snapshot
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
NeuroPace Lowers FY2026 Sales Guidance from $99.500M-$101.500M to $91.000M-$92.000M vs $100.321M Est
NeuroPace Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $23.100M Miss $27.158M Estimate
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
NeuroPace, Inc. Q2 2026 Earnings Call Summary
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.